Neuroscience
From The Boston Globe:
-
Anthony H. Risser | neuroscience | neuropsychology | brain
- Business World: Biogen Idec, Elan, & Tysabri (natalizumab) And Ms
From the FDA: FOR IMMEDIATE RELEASE P06-25 February 16, 2006 Media Inquiries: Susan Cruzan, 301-827-6242 Consumer Inquiries: 888-INFO-FDA FDA Allows Clinical Studies of Tysabri (natalizumab) for Treatment of MS to Proceed The Food and...
- Business World: Biogen Idec, Elan, Tysabri (natalizumab), And Multiple Sclerosis
From Bloomberg via the New York Times:Move to Reinstate Multiple Sclerosis Drug Published: September 21, 2005 By Bloomberg News Biogen Idec Inc. and the Elan Corporation said yesterday that they would seek federal regulatory approval to resume sales...
- Business World: Biogen Idec, Elan, & Tysabri (natalizumab) (cont.)
Additional information in follow-up to this morning's Boston Globe report, from Bloomberg:Elan, Biogen Decline on Report of New Tysabri Illness June 2 (Bloomberg) -- Shares of Elan Corp. and Biogen Idec Inc. tumbled after a fourth possible case of...
- Business World: Biogen Idec, Elan, & Tysabri (natalizumab)
From today's Boston Globe:A fourth death may be tied to Biogen's MS drug Finding could be blow to marketplace hopes By Jeffrey Krasner, Boston Globe Staff June 2, 2005 Biogen Idec Inc. has told the Food and Drug Administration that a fourth...
- More M.s. Drug Woes: Avonex And 683699
Biogen and F.D.A. Issue Drug Warning By ANDREW POLLACK The New York Times Published: March 17, 2005 Biogen Idec's multiple sclerosis drug Avonex might cause severe liver damage in rare cases, the company and the Food and Drug Administration said...
Neuroscience
Business World: Biogen Idec, Protein Design Labs, & Daclizumab
From The Boston Globe:
Biogen cuts deal to refill drug lineup[ ... Read the full article ... ]
Biotech to pay Calif. firm for rights to help develop MS treatment, 2 others
By Jeffrey Krasner, Globe Staff
The Boston Globe
August 3, 2005
Making good on a promise to use a war chest of cash to replenish its drug pipeline, Biogen Idec Inc. of Cambridge yesterday said it was licensing three promising drug candidates from Protein Design Labs Inc.
In exchange for rights to codevelop three antibodies midway through human trials, Biogen Idec will pay Protein Design Labs $40 million, and buy $100 million of the Fremont, Calif., company's stock. If the three drug candidates are proven effective treatments for various diseases, Biogen Idec could pay an additional $660 million.
The deal includes codevelopment rights for Daclizumab, an antibody that has shown promise in preventing transplanted organ rejection and in treating asthma and multiple sclerosis. Positive news about Daclizumab trials underway could bolster Biogen Idec's multiple sclerosis franchise, which has faltered this year since the voluntary suspension of Tysabri, an MS treatment that resulted in unexpected illnesses in several patients who used it during clinical trials.
-
Anthony H. Risser | neuroscience | neuropsychology | brain
- Business World: Biogen Idec, Elan, & Tysabri (natalizumab) And Ms
From the FDA: FOR IMMEDIATE RELEASE P06-25 February 16, 2006 Media Inquiries: Susan Cruzan, 301-827-6242 Consumer Inquiries: 888-INFO-FDA FDA Allows Clinical Studies of Tysabri (natalizumab) for Treatment of MS to Proceed The Food and...
- Business World: Biogen Idec, Elan, Tysabri (natalizumab), And Multiple Sclerosis
From Bloomberg via the New York Times:Move to Reinstate Multiple Sclerosis Drug Published: September 21, 2005 By Bloomberg News Biogen Idec Inc. and the Elan Corporation said yesterday that they would seek federal regulatory approval to resume sales...
- Business World: Biogen Idec, Elan, & Tysabri (natalizumab) (cont.)
Additional information in follow-up to this morning's Boston Globe report, from Bloomberg:Elan, Biogen Decline on Report of New Tysabri Illness June 2 (Bloomberg) -- Shares of Elan Corp. and Biogen Idec Inc. tumbled after a fourth possible case of...
- Business World: Biogen Idec, Elan, & Tysabri (natalizumab)
From today's Boston Globe:A fourth death may be tied to Biogen's MS drug Finding could be blow to marketplace hopes By Jeffrey Krasner, Boston Globe Staff June 2, 2005 Biogen Idec Inc. has told the Food and Drug Administration that a fourth...
- More M.s. Drug Woes: Avonex And 683699
Biogen and F.D.A. Issue Drug Warning By ANDREW POLLACK The New York Times Published: March 17, 2005 Biogen Idec's multiple sclerosis drug Avonex might cause severe liver damage in rare cases, the company and the Food and Drug Administration said...